Publications

2023

Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor

JACC: Cardiovascular Interventions.16(1):36-46[DOI] 10.1016/j.jcin.2022.10.034.[PMID] .

PubMed·Publisher's Site

2022

Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.

European heart journal.43(10):959-967[DOI] 10.1093/eurheartj/ehab836.[PMID] 34918066.

29 citations·PubMed·Publisher's Site

2022

CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.

Journal of the American Heart Association.11(4):e024159-[DOI] 10.1161/JAHA.121.024159.[PMID] 35156424.

6 citations·PubMed·Publisher's Site

2022

Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.

European heart journal. Cardiovascular pharmacotherapy.8(5):452-461[DOI] 10.1093/ehjcvp/pvab042.[PMID] 34114623.

2 citations·PubMed·Publisher's Site

2022

Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease

Journal of Thrombosis and Thrombolysis.54(3):461-469[DOI] 10.1007/s11239-022-02696-4.[PMID] .

PubMed·Publisher's Site

2022

Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.

Clinical pharmacology and therapeutics.112(1):146-155[DOI] 10.1002/cpt.2612.[PMID] 35429163.

1 citations·PubMed·Publisher's Site

2022

P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.

Nature reviews. Cardiology.19(12):829-844[DOI] 10.1038/s41569-022-00725-6.[PMID] 35697777.

3 citations·PubMed·Publisher's Site

2022

Patterns and Outcomes of Dual Antiplatelet Therapy Discontinuation After Percutaneous Coronary Intervention.

JACC. Cardiovascular interventions.15(8):807-809[DOI] 10.1016/j.jcin.2022.02.048.[PMID] 35450680.

PubMed·Publisher's Site

2022

Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.

Thrombosis and haemostasis.122(8):1341-1351[DOI] 10.1055/a-1730-8725.[PMID] 34983074.

1 citations·PubMed·Publisher's Site

2022

Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.

European heart journal. Cardiovascular pharmacotherapy.8(7):728-737[DOI] 10.1093/ehjcvp/pvac022.[PMID] 35353154.

1 citations·PubMed·Publisher's Site

2022

Reply: The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?

JACC. Cardiovascular interventions.15(2):230-231[DOI] 10.1016/j.jcin.2021.12.002.[PMID] 35057998.

PubMed·Publisher's Site

2022

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.

European heart journal. Cardiovascular pharmacotherapy.8(7):677-686[DOI] 10.1093/ehjcvp/pvab070.[PMID] 34519777.

30 citations·PubMed·Publisher's Site

2021

Dual pathway inhibition in atherothrombosis prevention: yes, now we can!

Minerva cardiology and angiology.():-[DOI] 10.23736/S2724-5683.21.05867-1.[PMID] 34761666.

1 citations·PubMed·Publisher's Site

2021

Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study

BMJ Open Diabetes Research & Care.9(1):e001939-[DOI] 10.1136/bmjdrc-2020-001939.[PMID] 33637605.

6 citations·PubMed·Publisher's Site

2021

Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations.

Expert review of clinical pharmacology.14(8):963-978[DOI] 10.1080/17512433.2021.1927709.[PMID] 33993817.

14 citations·PubMed·Publisher's Site

2021

Genotype-Guided Antiplatelet Therapy in Patients With Coronary Artery Disease.

JACC. Cardiovascular interventions.14(7):751-753[DOI] 10.1016/j.jcin.2021.02.005.[PMID] 33744206.

2 citations·PubMed·Publisher's Site

2021

Guided selection of antiplatelet therapy in acute coronary syndrome: Impact on outcomes and resource utilization.

International journal of cardiology.345():36-38[DOI] 10.1016/j.ijcard.2021.10.010.[PMID] 34678324.

5 citations·PubMed·Publisher's Site

2021

Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Lancet (London, England).397(10283):1470-1483[DOI] 10.1016/S0140-6736(21)00533-X.[PMID] 33865495.

66 citations·PubMed·Publisher's Site

2021

Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Clinical pharmacology and therapeutics.109(3):705-715[DOI] 10.1002/cpt.2039.[PMID] 32897581.

16 citations·PubMed·Publisher's Site

2021

Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.

JACC. Cardiovascular interventions.14(21):2410-2412[DOI] 10.1016/j.jcin.2021.07.051.[PMID] 34736741.

2 citations·PubMed·Publisher's Site

2021

Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention.

Trends in cardiovascular medicine.():-[DOI] 10.1016/j.tcm.2021.12.007.[PMID] 34936903.

8 citations·PubMed·Publisher's Site

2021

Typical atrial flutter from blunt cardiac injury: an atypical cause.

Journal of geriatric cardiology : JGC.18(2):155-157[DOI] 10.11909/j.issn.1671-5411.2021.02.009.[PMID] 33747066.

PubMed·Publisher's Site

2021

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor

Journal of Thrombosis and Thrombolysis.51(3):741-747[DOI] 10.1007/s11239-021-02386-7.[PMID] 33582955.

1 citations·PubMed·Publisher's Site

2020

Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention.

Clinical and translational science.13(3):473-481[DOI] 10.1111/cts.12729.[PMID] 31758664.

8 citations·PubMed·Publisher's Site

2020

Clopidogrel drug interactions: a review of the evidence and clinical implications.

Expert opinion on drug metabolism & toxicology.16(11):1079-1096[DOI] 10.1080/17425255.2020.1814254.[PMID] 32835535.

4 citations·PubMed·Publisher's Site

2020

Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.

Genetics in medicine : official journal of the American College of Medical Genetics.22(11):1919-[DOI] 10.1038/s41436-020-0931-1.[PMID] 32747766.

PubMed·Publisher's Site

2020

Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network.

Pharmacogenomics and personalized medicine.13():217-226[DOI] 10.2147/PGPM.S241599.[PMID] 32765043.

9 citations·PubMed·Publisher's Site

2020

Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.

Thrombosis and haemostasis.120(1):83-93[DOI] 10.1055/s-0039-1695772.[PMID] 31470444.

17 citations·PubMed·Publisher's Site

2020

Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.

Genetics in medicine : official journal of the American College of Medical Genetics.22(11):1898-1902[DOI] 10.1038/s41436-020-0894-2.[PMID] 32678355.

3 citations·PubMed·Publisher's Site

2020

Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.

Circulation.142(15):1500-1502[DOI] 10.1161/CIRCULATIONAHA.120.048770.[PMID] 33044856.

7 citations·PubMed·Publisher's Site

2020

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.

Journal of the American Heart Association.9(8):e015865-[DOI] 10.1161/JAHA.120.015865.[PMID] 32306797.

15 citations·PubMed·Publisher's Site

2020

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.

JACC. Basic to translational science.5(5):419-428[DOI] 10.1016/j.jacbts.2020.02.009.[PMID] 32478205.

15 citations·PubMed·Publisher's Site

2019

Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.

JACC. Cardiovascular interventions.12(16):1538-1549[DOI] 10.1016/j.jcin.2019.05.028.[PMID] 31377269.

19 citations·PubMed·Publisher's Site

2019

Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial.

Journal of the American Heart Association.8(6):e011139-[DOI] 10.1161/JAHA.118.011139.[PMID] 30857464.

24 citations·PubMed·Publisher's Site

2019

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.

JACC. Basic to translational science.4(7):763-775[DOI] 10.1016/j.jacbts.2019.07.011.[PMID] 31998847.

11 citations·PubMed·Publisher's Site

2019

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Circulation.139(14):1661-1670[DOI] 10.1161/CIRCULATIONAHA.118.038317.[PMID] 30630341.

70 citations·PubMed·Publisher's Site

2019

Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations.

Therapeutic advances in hematology.10():2040620719861475-[DOI] 10.1177/2040620719861475.[PMID] 31321012.

3 citations·PubMed·Publisher's Site

2019

Switching Oral Anticoagulant Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

JACC. Cardiovascular interventions.12(23):2342-2345[DOI] 10.1016/j.jcin.2019.10.017.[PMID] 31806215.

1 citations·PubMed·Publisher's Site

2019

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.

JACC. Cardiovascular interventions.12(16):1521-1537[DOI] 10.1016/j.jcin.2019.03.034.[PMID] 31202949.

247 citations·PubMed·Publisher's Site

2018

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.

Nature reviews. Cardiology.15(8):480-496[DOI] 10.1038/s41569-018-0049-1.[PMID] 29973709.

146 citations·PubMed·Publisher's Site

2018

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.

Journal of translational medicine.16(1):92-[DOI] 10.1186/s12967-018-1469-8.[PMID] 29642909.

30 citations·PubMed·Publisher's Site

2018

Diabetes and antiplatelet therapy: from bench to bedside.

Cardiovascular diagnosis and therapy.8(5):594-609[DOI] 10.21037/cdt.2018.05.09.[PMID] 30498684.

36 citations·PubMed·Publisher's Site

2018

Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy.

Progress in cardiovascular diseases.60(4-5):478-490[DOI] 10.1016/j.pcad.2017.12.004.[PMID] 29291426.

45 citations·PubMed·Publisher's Site

2018

Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.

Clinical pharmacology and therapeutics.104(4):664-674[DOI] 10.1002/cpt.1006.[PMID] 29280137.

73 citations·PubMed·Publisher's Site

2018

Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.

Circulation.137(23):2450-2462[DOI] 10.1161/CIRCULATIONAHA.118.033983.[PMID] 29526833.

41 citations·PubMed·Publisher's Site

2018

Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.

Journal of cardiovascular pharmacology and therapeutics.23(1):23-37[DOI] 10.1177/1074248417708617.[PMID] 28565918.

15 citations·PubMed·Publisher's Site

2018

Role of genetic testing in patients undergoing percutaneous coronary intervention.

Expert review of clinical pharmacology.11(2):151-164[DOI] 10.1080/17512433.2017.1353909.[PMID] 28689434.

49 citations·PubMed·Publisher's Site

2018

Standard- and Low-Dose Ticagrelor After Percutaneous Coronary Intervention: Finding the Balance for Patients With Stable Coronary Artery Disease.

Circulation.138(13):1301-1303[DOI] 10.1161/CIRCULATIONAHA.118.036240.[PMID] 30354428.

1 citations·PubMed·Publisher's Site

2018

The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts.

Expert review of hematology.11(1):5-12[DOI] 10.1080/17474086.2018.1400378.[PMID] 29091481.

17 citations·PubMed·Publisher's Site

2018

The Quest for the Optimal Periprocedural Antithrombotic Treatment Strategy in ACS Patients Undergoing PCI.

Journal of the American College of Cardiology.71(11):1243-1245[DOI] 10.1016/j.jacc.2018.01.040.[PMID] 29544608.

4 citations·PubMed·Publisher's Site

2017

Antithrombotic therapy for patients with STEMI undergoing primary PCI.

Nature reviews. Cardiology.14(6):361-379[DOI] 10.1038/nrcardio.2017.18.[PMID] 28230176.

65 citations·PubMed·Publisher's Site

2017

Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.

Thrombosis and haemostasis.117(5):940-947[DOI] 10.1160/TH16-09-0703.[PMID] 28300867.

18 citations·PubMed·Publisher's Site

2017

Crushed ticagrelor in comatose patients treated with primary percutaneous coronary intervention.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.12(14):1681-1683[DOI] 10.4244/EIJV12I14A276.[PMID] 28216470.

1 citations·PubMed·Publisher's Site

2017

De-Escalation of Platelet P2Y12 Receptor Inhibiting Therapy After Percutaneous Coronary Intervention: Does One Size Fit All?

JACC. Cardiovascular interventions.10(24):2571-2573[DOI] 10.1016/j.jcin.2017.10.007.[PMID] 29268887.

4 citations·PubMed·Publisher's Site

2017

Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y12 Receptor Inhibitors: How Real Is It?

JACC. Cardiovascular interventions.10(2):130-132[DOI] 10.1016/j.jcin.2016.11.021.[PMID] 28104205.

3 citations·PubMed·Publisher's Site

2017

Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus.

Thrombosis and haemostasis.117(1):201-203[DOI] 10.1160/TH16-08-0594.[PMID] 27786340.

6 citations·PubMed·Publisher's Site

2017

Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.

Journal of the American Heart Association.6(4):-[DOI] 10.1161/JAHA.117.005650.[PMID] 28356282.

29 citations·PubMed·Publisher's Site

2017

Institutional profile: University of Florida Health Personalized Medicine Program.

Pharmacogenomics.18(5):421-426[DOI] 10.2217/pgs-2017-0028.[PMID] 28346068.

47 citations·PubMed·Publisher's Site

2017

International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies.

Circulation.136(20):1955-1975[DOI] 10.1161/CIRCULATIONAHA.117.031164.[PMID] 29084738.

211 citations·PubMed·Publisher's Site

2017

In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor-Mediated Signaling in Ticagrelor-Treated Patients.

JACC. Cardiovascular interventions.10(13):1374-1375[DOI] 10.1016/j.jcin.2017.04.027.[PMID] 28683943.

7 citations·PubMed·Publisher's Site

2017

Oral trans-mucosal administration of ticagrelor: is this really the future?

Thrombosis and haemostasis.117(5):826-828[DOI] 10.1160/TH17-03-0177.[PMID] 28331923.

PubMed·Publisher's Site

2017

Reply: Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.

Journal of the American College of Cardiology.69(2):250-251[DOI] 10.1016/j.jacc.2016.09.982.[PMID] 28081837.

PubMed·Publisher's Site

2017

Switching from ticagrelor to clopidogrel: New answers and further questions.

Thrombosis and haemostasis.117(2):207-208[DOI] 10.1160/TH16-12-0909.[PMID] 28004060.

3 citations·PubMed·Publisher's Site

2017

Switching P2Y12 Receptor Inhibiting Therapies.

Interventional cardiology clinics.6(1):67-89[DOI] 10.1016/j.iccl.2016.08.006.[PMID] 27886824.

5 citations·PubMed·Publisher's Site

2017

The role of oral anticoagulant therapy in patients with acute coronary syndrome.

Therapeutic advances in hematology.8(12):353-366[DOI] 10.1177/2040620717733691.[PMID] 29204262.

15 citations·PubMed·Publisher's Site

2016

A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.

European heart journal.37(35):2722-30[DOI] 10.1093/eurheartj/ehv744.[PMID] 26848148.

48 citations·PubMed·Publisher's Site

2016

A Safety Evaluation of Cangrelor in Patients Undergoing PCI.

Expert opinion on drug safety.15(2):275-85[DOI] 10.1517/14740338.2016.1133585.[PMID] 26680584.

11 citations·PubMed·Publisher's Site

2016

Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease.

Circulation journal : official journal of the Japanese Circulation Society.80(4):791-801[DOI] 10.1253/circj.CJ-16-0208.[PMID] 26984587.

16 citations·PubMed·Publisher's Site

2016

Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.

Journal of the American College of Cardiology.67(17):1994-2004[DOI] 10.1016/j.jacc.2016.02.045.[PMID] 27012781.

86 citations·PubMed·Publisher's Site

2016

Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention.

JACC. Cardiovascular interventions.9(3):228-230[DOI] 10.1016/j.jcin.2015.11.022.[PMID] 26777325.

PubMed·Publisher's Site

2016

Dual antiplatelet therapy after coronary stenting.

Expert opinion on pharmacotherapy.17(13):1775-87[DOI] 10.1080/14656566.2016.1202924.[PMID] 27309035.

9 citations·PubMed·Publisher's Site

2016

Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.

Thrombosis and haemostasis.115(3):622-31[DOI] 10.1160/TH15-06-0467.[PMID] 26633836.

21 citations·PubMed·Publisher's Site

2016

Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.

Journal of the American College of Cardiology.67(6):603-613[DOI] 10.1016/j.jacc.2015.11.044.[PMID] 26868683.

35 citations·PubMed·Publisher's Site

2016

Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors.

Thrombosis and haemostasis.116(6):1060-1069[DOI] .[PMID] 27488362.

6 citations·PubMed·Publisher's Site

2016

Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.

Circulation.134(11):780-92[DOI] 10.1161/CIRCULATIONAHA.116.023402.[PMID] 27559041.

72 citations·PubMed·Publisher's Site

2016

Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.

JACC. Cardiovascular interventions.9(11):1089-98[DOI] 10.1016/j.jcin.2016.02.039.[PMID] 27013060.

30 citations·PubMed·Publisher's Site

2016

Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.

Journal of the American College of Cardiology.67(10):1145-1154[DOI] 10.1016/j.jacc.2015.12.062.[PMID] 26965534.

87 citations·PubMed·Publisher's Site

2016

Switching P2Y12-receptor inhibitors in patients with coronary artery disease.

Nature reviews. Cardiology.13(1):11-27[DOI] 10.1038/nrcardio.2015.113.[PMID] 26283269.

129 citations·PubMed·Publisher's Site

2016

The Conundrum of Platelet P2Y12 Inhibition in ST-Segment Elevation Myocardial Infarction.

Circulation journal : official journal of the Japanese Circulation Society.80(12):2429-2431[DOI] .[PMID] 27795489.

3 citations·PubMed·Publisher's Site

2016

The Paradox of Smoking and Clopidogrel Effect　- Dr Jekyll or Mr Hyde?

Circulation journal : official journal of the Japanese Circulation Society.80(7):1529-31[DOI] 10.1253/circj.CJ-16-0508.[PMID] 27302849.

2 citations·PubMed·Publisher's Site

2016

Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction.

Trends in cardiovascular medicine.26(4):321-34[DOI] 10.1016/j.tcm.2015.08.002.[PMID] 26391344.

3 citations·PubMed·Publisher's Site

2015

[Non-cardiac surgery in patients with previous percutaneous coronary intervention according to the 2014 European guidelines].

Giornale italiano di cardiologia (2006).16(5):277-80[DOI] 10.1714/1870.20424.[PMID] 25994462.

PubMed·Publisher's Site

2015

Defining the link between chronic kidney disease, high platelet reactivity, and clinical outcomes in clopidogrel-treated patients undergoing percutaneous coronary intervention.

Circulation. Cardiovascular interventions.8(6):e002760-[DOI] 10.1161/CIRCINTERVENTIONS.115.002760.[PMID] 26056251.

11 citations·PubMed·Publisher's Site

2015

Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.

JACC. Cardiovascular interventions.8(11):1457-1467[DOI] 10.1016/j.jcin.2015.02.030.[PMID] 26404199.

63 citations·PubMed·Publisher's Site

2015

Novel antiplatelet agents in acute coronary syndrome.

Nature reviews. Cardiology.12(1):30-47[DOI] 10.1038/nrcardio.2014.156.[PMID] 25286881.

231 citations·PubMed·Publisher's Site

2015

Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike.

Progress in cardiovascular diseases.58(3):267-77[DOI] 10.1016/j.pcad.2015.08.009.[PMID] 26277706.

13 citations·PubMed·Publisher's Site

2015

Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.

JACC. Cardiovascular interventions.8(8):1075-1083[DOI] 10.1016/j.jcin.2015.02.022.[PMID] 26117466.

4 citations·PubMed·Publisher's Site

2015

Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.

Future cardiology.11(5):547-64[DOI] 10.2217/fca.15.50.[PMID] 26406386.

13 citations·PubMed·Publisher's Site

2015

Reply: elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary intervention.

Journal of the American College of Cardiology.65(16):1714-1715[DOI] 10.1016/j.jacc.2014.12.069.[PMID] 25908082.

PubMed·Publisher's Site

2015

Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists.

Journal of thrombosis and thrombolysis.40(1):118-25[DOI] 10.1007/s11239-014-1130-1.[PMID] 25129122.

10 citations·PubMed·Publisher's Site

2014

Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.

Journal of cardiovascular translational research.7(1):53-63[DOI] 10.1007/s12265-013-9535-3.[PMID] 24395495.

21 citations·PubMed·Publisher's Site

2014

Erratum to: Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.

Journal of thrombosis and thrombolysis.37(3):358-[DOI] 10.1007/s11239-013-1003-z.[PMID] 24101257.

PubMed·Publisher's Site

2014

Impact of cigarette smoking on P2Y12 receptor binding activity before and after clopidogrel therapy in patients with coronary artery disease.

Journal of cardiovascular translational research.7(1):47-52[DOI] 10.1007/s12265-013-9530-8.[PMID] 24357254.

5 citations·PubMed·Publisher's Site

2014

Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.

Journal of the American College of Cardiology.64(10):1005-14[DOI] 10.1016/j.jacc.2014.06.1170.[PMID] 25190236.

128 citations·PubMed·Publisher's Site

2014

Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery.

Current opinion in cardiology.29(6):553-63[DOI] 10.1097/HCO.0000000000000104.[PMID] 25144343.

5 citations·PubMed·Publisher's Site

2014

Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.

JACC. Cardiovascular interventions.7(4):426-34[DOI] 10.1016/j.jcin.2013.11.019.[PMID] 24630878.

27 citations·PubMed·Publisher's Site

2014

Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.

Journal of thrombosis and thrombolysis.37(2):131-8[DOI] 10.1007/s11239-013-0979-8.[PMID] 23943337.

12 citations·PubMed·Publisher's Site

2014

Platelet function testing in contemporary clinical and interventional practice.

Current treatment options in cardiovascular medicine.16(5):300-[DOI] 10.1007/s11936-014-0300-y.[PMID] 24652579.

31 citations·PubMed·Publisher's Site

2014

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.

Vascular health and risk management.10():177-88[DOI] 10.2147/VHRM.S36045.[PMID] 24729713.

14 citations·PubMed·Publisher's Site

2013

Cangrelor: a review on pharmacology and clinical trial development.

Expert review of cardiovascular therapy.11(10):1279-91[DOI] 10.1586/14779072.2013.837701.[PMID] 24138516.

44 citations·PubMed·Publisher's Site

2013

Effect of cardiac resynchronization therapy on left atrial reverse remodeling: role of echocardiographic AV delay optimization.

International journal of cardiology.167(4):1456-60[DOI] 10.1016/j.ijcard.2012.04.046.[PMID] 22560916.

9 citations·PubMed·Publisher's Site

2013

Effects of Cangrelor in Prasugrel Treated Patients: a Pharmacodynamic in Vitro Investigation

Circulation.128(22, S):-[DOI] .[PMID] .

PubMed·Publisher's Site

2013

Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation.

Thrombosis and haemostasis.110(4):777-84[DOI] 10.1160/TH13-05-0400.[PMID] 23884248.

6 citations·PubMed·Publisher's Site

2013

Indexed maximal left atrial volume predicts response to cardiac resynchronization therapy.

International journal of cardiology.168(4):3629-33[DOI] 10.1016/j.ijcard.2013.05.028.[PMID] 23725913.

12 citations·PubMed·Publisher's Site

2013

Pharmacodynamic Effects of Ev-077 in Patients With Diabetes Mellitus On Clopidogrel Monotherapy: Results of An in Vitro Pilot Investigation

Journal of the American College of Cardiology.61():E1830-[DOI] .[PMID] .

PubMed·Publisher's Site

2013

Platelet function profiles in patients with diabetes mellitus.

Journal of cardiovascular translational research.6(3):329-45[DOI] 10.1007/s12265-013-9449-0.[PMID] 23404189.

39 citations·PubMed·Publisher's Site

2013

Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.

Therapeutic advances in cardiovascular disease.7(4):197-213[DOI] 10.1177/1753944713487781.[PMID] 23818658.

42 citations·PubMed·Publisher's Site

Show More